322 related articles for article (PubMed ID: 26696321)
1. Bendamustine associated immune suppression and infections during therapy of hematological malignancies.
Gafter-Gvili A; Polliack A
Leuk Lymphoma; 2016; 57(3):512-9. PubMed ID: 26696321
[TBL] [Abstract][Full Text] [Related]
2. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
3. Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Penne M; Sarraf Yazdy M; Nair KS; Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):637-644. PubMed ID: 28797620
[TBL] [Abstract][Full Text] [Related]
4. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
7. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
[No Abstract] [Full Text] [Related]
8. Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.
Suzuki M; Koyama D; Ikeda S; Sukegawa M; Teshirogi M; Misawa K; Tsunoda S
J Clin Exp Hematop; 2022 Jun; 62(2):91-98. PubMed ID: 35153257
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
11. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ; Delgado J; Loscertales J; Sastre JL; Peña A; Olave MT; Osorio S; de la Fuente A; Salar A; Grande C; Pérez Ceballos E; Debén G; Echeveste A; Casado F; de la Rubia J; Lahuerta JJ; Mateos MV
Eur J Haematol; 2016 May; 96(5):532-40. PubMed ID: 26179864
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials.
Gafter-Gvili A; Gurion R; Raanani P; Shpilberg O; Vidal L
Hematol Oncol; 2017 Dec; 35(4):424-431. PubMed ID: 27734524
[TBL] [Abstract][Full Text] [Related]
13. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
Gafter-Gvili A; Ribakovsky E; Mizrahi N; Avigdor A; Aviv A; Vidal L; Ram R; Perry C; Avivi I; Kedmi M; Nagler A; Raanani P; Gurion R
Leuk Lymphoma; 2016; 57(1):63-9. PubMed ID: 25944378
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N; Hartley S; Ahearne M; Kasenda B; Beech A; Knight H; Balotis C; Kennedy B; Wagner S; Dyer MJS; Smith D; McMillan AK; Miall F; Bishton M; Fox CP
Br J Haematol; 2019 Mar; 184(6):957-968. PubMed ID: 30548597
[TBL] [Abstract][Full Text] [Related]
15. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.
Ninkovic M; Fiegl M; Mian M; Mondello P; Kocher F; Waldthaler C; Verdorfer I; Steurer M; Gastl G; Pircher A
Anticancer Res; 2015 Sep; 35(9):5129-39. PubMed ID: 26254418
[TBL] [Abstract][Full Text] [Related]
16. Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.
Fung M; Jacobsen E; Freedman A; Prestes D; Farmakiotis D; Gu X; Nguyen PL; Koo S
Clin Infect Dis; 2019 Jan; 68(2):247-255. PubMed ID: 29800121
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
18. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine: role and evidence in lymphoma therapy, an overview.
Derenzini E; Zinzani PL; Cheson BD
Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
